Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Globenewswire·2025-11-05 16:45
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease Allschwil, Switzerland – November 05, 2025Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX, November 5–9, 2025. A ...